CLINICAL RELEVANCE: DRUG–DRUG INTERACTION,PHARMACOKINETICS,PHARMACODYNAMICS, AND TOXICITY - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 831

231. Gupta A, Zhang Y, Unadkat JD, Mao Q. 2004. HIV protease inhibitors are inhibitors but
not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol
Exp Ther 310: 334-341.
232. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM. 2000. Fumitremorgin C
reverses multidrug resistance in cells transfected with the breast cancer resistance protein.
Cancer Res 60: 47-50.
233. Allen JD, van Loevezijn A, Lakhai JM, van der valk M, van Tellingen O, Reid G, Schellens
JHM, Koomen GJ, Schinkel AH. 2002. Potent and specific inhibition of the breast cancer
resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue
of fumitremorgin C. Mol Cancer Ther 1: 417-425.
234. van Loevezijn A, Allen JD, Schinkel AH, Koomen GJ. 2001. Inhibition of BCRP-mediated
drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorg Med Chem Lett 11:
29-32.
235. Yang CH, Chen YC, Kuo ML. 2003. Novobiocin sensitizes BCRP/MXR/ABCP overex-
pressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone.
Anticancer Res 23: 2519-2523.
236. Woehlecke H, Osada H, Herrmann A, Lage H. 2003. Reversal of breast cancer resistance
protein-mediated drug resistance by tryprostatin A. Int J Cancer 107: 721-728.
237. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi
L, Nemet K, Sarkadi B. 2004. High-affinity interaction of tyrosine kinase inhibitors with
the ABCG2 multidrug transporter. Mol Pharmacol 65: 1485-1495.
238. Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins
JJ, Gilbertson R, Germain GS, Harwood FC, Houghton PJ. 2004. Gefitinib enhances the
antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res 64: 7491-
7499.
239. Yanase K, Tsukahara S, Asada S, Ishikawa E, Imai Y, Sugimoto Y. 2004. Gefitinib
reverses breast cancer resistance protein-mediated drug resistance. Mol Cancer Ther 3:
1119-1125.
240. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E,
Traxler P. 2004. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) trans-
porter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 64: 2333-
2337.
241. Gupta A, Dai Y, Vethanayagam RR, Hebert MF, Thummel KE, Unadkat JD, Ross DD,
Mao Q. 2006. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human
breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and
topotecan. Cancer Chemother Pharmacol 58: 374-383.
242. Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Webster LO, Barnaby
RJ, Vitulli G, Bertolotti L, Read KD, Serabjit-Singh CJ. 2004. The systemic exposure of
an N -methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and
breast cancer resistance protein efflux transporters. Drug Metab Dispos 32: 722-726.
243. Cisternino S, Mercier C, Bourasset F, Roux F, Scherrmann JM. 2004. Expression, up-
regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse
blood-brain barrier. Cancer Res 64: 3296-3301.
244. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper
RJ, Borst P, Pinedo HM, Jansen G. 1999. Antifolate resistance mediated by the multidrug
resistance proteins MRP1 and MRP2. Cancer Res 59: 2532-2535.